Rapid Development of High-Level Resistance to Dolutegravir with Emergence of T97A Mutation in 2 Treatment-Experienced Individuals with Baseline Partial Sensitivity to Dolutegravir

Abstract

HIV integrase mutation T97A emerges after suboptimal therapy with integrase strand transfer inhibitors (INSTIs), but the contribution of T97A to dolutegravir resistance remains uncertain. Here we report >10-fold increase in dolutegravir resistance after the single addition of T97A in 2 individuals with prior INSTI resistance receiving dolutegravir salvage therapy.